Literature DB >> 19330555

Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab.

Takashi Sonoki1, Yaqiong Li2, Setsuko Miyanishi3, Hirokazu Nakamine4, Nobuyoshi Hanaoka5, Hiroshi Matsuoka5, Ichiro Mori2, Hideki Nakakuma5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19330555     DOI： 10.1007/s12185-009-0295-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

1.  Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.

Authors:  Akihiro Tomita; Junji Hiraga; Hitoshi Kiyoi; Manabu Ninomiya; Takumi Sugimoto; Masafumi Ito; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 2.  Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

Authors:  Bruce D Cheson; John P Leonard
Journal:  N Engl J Med       Date:  2008-08-07       Impact factor: 91.245

3.  CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.

Authors:  T Kinoshita; H Nagai; T Murate; H Saito
Journal:  J Clin Oncol       Date:  1998-12       Impact factor: 44.544

4.  Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

Authors:  T A Davis; D K Czerwinski; R Levy
Journal:  Clin Cancer Res       Date:  1999-03       Impact factor: 12.531

Review 5.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

6.  CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.

Authors:  T Alvaro-Naranjo; J Jaén-Martínez; J Gumá-Padró; R Bosch-Príncep; M T Salvadó-Usach
Journal:  Ann Hematol       Date:  2003-07-31       Impact factor: 3.673

7.  Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease.

Authors:  M Crescenzi; M Seto; G P Herzig; P D Weiss; R C Griffith; S J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205
  7 in total
  6 in total

1.  Eradication of melanomas by targeted elimination of a minor subset of tumor cells.

Authors:  Patrick Schmidt; Caroline Kopecky; Andreas Hombach; Paola Zigrino; Cornelia Mauch; Hinrich Abken
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

Review 2.  Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.

Authors:  Berna Bozkurt Duman; Berksoy Sahin; Melek Ergin; Birol Guvenc
Journal:  Med Oncol       Date:  2011-07-31       Impact factor: 3.064

3.  Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.

Authors:  Kevin P Nishimoto; Taylor Barca; Aruna Azameera; Amani Makkouk; Jason M Romero; Lu Bai; Mary M Brodey; Jackie Kennedy-Wilde; Hui Shao; Stephanie Papaioannou; Amy Doan; Cynthia Masri; Ngoc T Hoang; Hayden Tessman; Vidhya Dhevi Ramanathan; Ana Giner-Rubio; Frank Delfino; Kriti Sharma; Kevin Bray; Matthew Hoopes; Daulet Satpayev; Ranjita Sengupta; Marissa Herrman; Stewart E Abbot; Blake T Aftab; Zili An; Swapna Panuganti; Sandra M Hayes
Journal:  Clin Transl Immunology       Date:  2022-02-02

4.  Expanding anti-CD38 immunotherapy for lymphoid malignancies.

Authors:  Xu Wang; Xinfang Yu; Wei Li; Praveen Neeli; Ming Liu; Ling Li; Mingzhi Zhang; Xiaosheng Fang; Ken H Young; Yong Li
Journal:  J Exp Clin Cancer Res       Date:  2022-06-28

5.  De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.

Authors:  Takashi Tokunaga; Akihiro Tomita; Keiki Sugimoto; Kazuyuki Shimada; Chisako Iriyama; Tatsuya Hirose; Mizuho Shirahata-Adachi; Yasuhiro Suzuki; Hiroki Mizuno; Hitoshi Kiyoi; Naoko Asano; Shigeo Nakamura; Tomohiro Kinoshita; Tomoki Naoe
Journal:  Cancer Sci       Date:  2013-12-22       Impact factor: 6.716

6.  Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma.

Authors:  Tomonori Higuchi; Yumiko Hashida; Ayuko Taniguchi; Mikio Kamioka; Masanori Daibata
Journal:  Sci Rep       Date:  2017-09-08       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.